DPP4 and type 2 diabetes mellitus: In a 26-week study investigating the efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin plus metformin initial combination therapy, the combination therapy compared favorable to monotherapy of either drug in drug-naïve T2D patients (HbA1c = 7.5–10.0%).